EGRX (OTC)
EAGLE PHARMS INC
$0.250000
-0.100000 (-28.57%)
Prev close: $0.350000
Company Information
- Exchange
- OTC Link
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Michael Graves
- Asset Type
- otc
- Website
- —
Fundamentals
- Market Cap
- $3.25M
- Employees
- 135
- P/E (TTM)
- —
- P/B (TTM)
- —
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
3
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2023 (Q2)
|
$1.18 | $1.07 | +0.1090 | +10.18% |
|
Mar 2023 (Q1)
|
$1.26 | $1.07 | +0.1890 | +17.65% |
|
Dec 2022 (Q4)
|
$1.10 | $0.85 | +0.2534 | +29.93% |
|
Sep 2022 (Q3)
|
$1.12 | $0.92 | +0.1952 | +21.11% |
Financial Statements
| Revenues | $257.55M |
| Benefits Costs and Expenses | $228.38M |
| Cost Of Revenue | $73.27M |
| Costs And Expenses | $216.55M |
| Gross Profit | $184.28M |
| Nonoperating Income/Loss | -$11.84M |
| Operating Expenses | $143.28M |
| Selling, General, and Administrative Expenses | $103.22M |
| Research and Development | $35.65M |
| Operating Income/Loss | $41.01M |
| Income/Loss From Continuing Operations After Tax | $11.95M |
| Income/Loss From Continuing Operations Before Tax | $29.17M |
| Income Tax Expense/Benefit | $17.22M |
| Interest Expense, Operating | $6.09M |
| Net Income/Loss | $11.95M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $11.95M |
| Net Income/Loss Available To Common Stockholders, Basic | $11.95M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.92 |
| Diluted Earnings Per Share | $0.91 |
| Basic Average Shares | 26,269,682 |
| Diluted Average Shares | 39,488,984 |
| Assets | $404.82M |
| Current Assets | $187.25M |
| Inventory | $42.48M |
| Other Current Assets | $144.77M |
| Noncurrent Assets | $217.57M |
| Fixed Assets | $1.01M |
| Intangible Assets | $107.41M |
| Other Non-current Assets | $109.15M |
| Liabilities | $152.78M |
| Current Liabilities | $86.63M |
| Accounts Payable | $15.84M |
| Other Current Liabilities | $70.79M |
| Noncurrent Liabilities | $66.15M |
| Long-term Debt | $71.25M |
| Equity | $252.04M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $252.04M |
| Liabilities And Equity | $404.82M |
| Net Cash Flow From Operating Activities | -$9.32M |
| Net Cash Flow From Operating Activities, Continuing | -$9.32M |
| Net Cash Flow From Investing Activities | -$23.81M |
| Net Cash Flow From Investing Activities, Continuing | -$23.81M |
| Net Cash Flow From Financing Activities | $11.92M |
| Net Cash Flow From Financing Activities, Continuing | $11.92M |
| Net Cash Flow | -$21.21M |
| Net Cash Flow, Continuing | -$21.21M |
| Comprehensive Income/Loss | $8.56M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $8.56M |
| Other Comprehensive Income/Loss | $8.56M |
| Other Comprehensive Income/Loss Attributable To Parent | -$3.39M |